白细胞介素 17A（IL-17A）是IL-17细胞因子家族的一个重要成员，主要由T辅助17（Th17）细胞产生。其他细胞，如CD8+ T细胞、γδ T细胞、自然杀伤T细胞和固有淋巴样细胞等也可以产生IL-17A。在健康个体中，IL-17A具有保护宿主的能力，但过度升高的IL-17A与自身免疫疾病和癌症的发展相关。单克隆抗体（mAbs）靶向IL-17A（如ixekizumab和secukinumab）或IL-17A受体（IL-17RA）（如brodalumab）将被研究作为这些疾病的潜在治疗方法。目前，在自身免疫疾病中应用靶向IL-17A的药物将为肿瘤治疗提供新的思路，其与免疫检查点抑制剂的联合应用已成为研究热点。本文综述了IL-17A的作用机制及抗IL-17A抗体的应用，重点关注了在结直肠癌（CRC）、肺癌、胃癌和乳腺癌等多种肿瘤中IL-17A作用机制和治疗阻断的研究进展。此外，我们还包括了在肿瘤领域治疗阻断的结果，以及IL-17A信号调节的最新进展。版权所有©2023 Elsevier B.V. 发布。

Interleukin 17A (IL-17A) is a major member of the IL-17 cytokine family and is produced mainly by T helper 17 (Th17) cells. Other cells such as CD8+ T cells, γδ T cells, natural killer T cells and innate lymphoid-like cells can also produce IL-17A. In healthy individuals, IL-17A has a host-protective capacity, but excessive elevation of IL-17A is associated with the development of autoimmune diseases and cancer. Monoclonal antibodies (mAbs) targeting IL-17A (e.g., ixekizumab and secukinumab) or IL-17A receptor (IL-17RA) (e.g., brodalumab) would be investigated as potential treatments for these diseases. Currently, the application of IL-17A-targeted drugs in autoimmune diseases will provide new ideas for the treatment of tumors, and its combined application with immune checkpoint inhibitors has become a research hotspot. This article reviews the mechanism of action of IL-17A and the application of anti-IL-17A antibodies, focusing on the research progress on the mechanism of action and therapeutic blockade of IL-17A in various tumors such as colorectal cancer (CRC), lung cancer, gastric cancer and breast cancer. Moreover, we also include the results of therapeutic blockade in the field of cancer as well as recent advances in the regulation of IL-17A signaling.Copyright © 2023. Published by Elsevier B.V.